# US 2003/0211505 A1 · In vivo assay for identifying nucelic acid sequences involved in alveolar loss, development and nucleic acid sequences identifield thereby

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0211505 A1
- Document ID: US20030211505A1
- Status: Published application
- Kind: A1
- Application number: 10/275,156
- Filed: 2003-04-01
- Published: 2003-11-13
- Earliest claimed: 2003-04-01
- Inventors: Donald Massaro; Gloria De Carlo Massaro; Wai-Yee Chan
- Web page: https://patentgrep.com/patent/US20030211505A1

## CPC

- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 2600/158: Expression markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

A novel assay system for identifying nucleic acid sequences polypeptides involved in alveolar function, development and turnover is provided. These nucleic acid sequences and polypeptides have application as therapeutics for pulmonary diseases and conditions, and in screening methods for identifying compounds that “turn on” or “turn off” these nucleic acid sequences.

## Claims

### Claim 1

An assay method for identifying nucleic acid sequences or polypeptides that regulate at least one of alveolar turnover, development, function and/or repair, comprising the following steps:
(i) subjecting a non-human mammal to nutrient deprivation conditions that result in said mammal exhibiting alveolar abnormalities and dysfunction;
(ii) obtaining a lung tissue or cell sample from said mammal while nutrient deprivation conditions and alveolar abnormalities are present;
(iii) thereafter subjecting said non-human mammal to adequate nutrition (“refeeding”) in order to at least partially restore said alveolar abnormalities and/or dysfunction;
(iv) obtaining at least one lung tissue or cell sample from said animal after adequate nutrition (“refeeding”) has been reinstituted; and
(v) comparing the nucleic sequences that are present in the cell sample of (ii) and (iv) in order to identify nucleic acid sequences that are putatively involved in regulation of at least one of alveolar turnover, development, function, and repair.

### Claim 2 (depends on 1)

The assay method of claim 1, wherein the comparison step (v) is effected by at least one method selected from the group consisting of subtractive hybridization, differential hybridization, gene chip analysis, serial analysis of gene expression, and differential display.

### Claim 3 (depends on 1)

The assay method of claim 1, wherein the comparison step (v) is effected by differential display.

### Claim 4 (depends on 3)

The assay method of claim 3, which further comprises sequencing nucleic acid sequences that are only present in cell sample (iv).

### Claim 5 (depends on 4)

The assay method of claim 4, which further comprises constructing probes corresponding to said sequences, and using said probes to screen a human cDNA, or genomic library.

### Claim 6 (depends on 5)

The assay method of claim 5, wherein said sequences are compared to the sequenced human genome in order to identify nucleic acid sequences that are at least 75% homologous thereto (based on sequence identity).

### Claim 7 (depends on 5)

The assay method of claim 5, wherein said sequences are compared to the sequenced human genome to identify nucleic acid sequences that are at least 90% homologous thereto (based on sequence identity).

### Claim 8 (depends on 1)

A method for identifying compounds that regulate at least one of alveolar turnover, function, development, and repair, comprising obtaining a regulatory (promoter) sequence from a nucleic acid sequence identified according to claim 1, operably linking said regulatory sequence to a DNA encoding a detectable protein, introducing said operably linked regulatory sequence and DNA encoding a detectable protein in a cell that provides for the expression thereof, and contacting said cell with compounds that are being screened for their potential ability to modulate alveolar turnover, function, report or regeneration, and selecting compounds that modulate at least one of alveolar turnover, repair and regeneration function based on their ability to “turn on” or “turn off” said regulatory sequence as evidenced by expression or absence of expression of the detectable protein.

### Claim 9 (depends on 8)

The method of claim 8, wherein said detectable protein is GFP.

### Claim 10 (depends on 8)

The method of claim 8, wherein said tested compound is a retinoid compound.

### Claim 11 (depends on 1)

The method of claim 1, wherein said cell also expresses the gene product normally expressed by said regulatory sequence.

### Claim 12 (depends on 1)

The method of claim 1, wherein said identified nucleic acid sequence or sequences are used to identify the corresponding human chromosomal locus or loci that comprise genes involved in alveolar turnover, function, development, and repair.

### Claim 13 (depends on 1)

A nucleic acid sequence identified by the method of claim 1.

### Claim 14

A polypeptide encoded by said nucleic acid sequence.
